A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast Cancer

NCT03429101 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

6

Enrollment

INDUSTRY

Sponsor class

Stopped Dose limiting toxicity

Conditions

Breast Cancer

Interventions

DRUG: Poziotinib
DRUG: T-DM1

Sponsor

Spectrum Pharmaceuticals, Inc